MoonLake Immunotherapeutics is a clinical-stage biopharmaceuticals company.
MoonLake Immunotherapeutics has raised $200.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
MoonLake Immunotherapeutics's investors include Cormorant Asset Management, RTW Investments, Hercules Capital, Biotechnology Value Fund, Surveyor Capital.
MoonLake Immunotherapeutics is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics is a clinical-stage biopharmaceuticals company.
MoonLake Immunotherapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MoonLake Immunotherapeutics — Funding & Investors." VCBacked, June 23, 2026, https://www.vcbacked.co/company/moonlake-immunotherapeutics. Accessed September 4, 2026.
VCBacked. (2026). MoonLake Immunotherapeutics — Funding & Investors. Retrieved September 4, 2026, from https://www.vcbacked.co/company/moonlake-immunotherapeutics
{{cite web |title=MoonLake Immunotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/moonlake-immunotherapeutics |website=VCBacked |access-date=September 4, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated